• 1
    Li C, Balluz LS, Ford ES, Okoro CA, Zhao G, Pierannunzi C. A comparaison of prevalence estimates for selected health indicators and chronic diseases or conditions from the behavioral risk factor surveillance survey, the National Health Interview Survey, and the National Health and Nutrition Examination Survey, 2007-2008. Prev Med 2012;54:381-387.
  • 2
    Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab 2004;30:569-572.
  • 3
    Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. An update of the 1997 American Heart Association Scientific statement on obesity and heart disease from the obesity committee of the council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.
  • 4
    Boulanger CM, Amabile N, Tedgui A. Circulating microparticles—a potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006;48:180-186.
  • 5
    Falati S, Liu QD, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197:1585-1598.
  • 6
    Liu ML, Williams KJ. Microvesicles: potential markers and mediators of endothelial dysfunction. Curr Opin Endocrinol Diabetes Obes 2012;19:121-127.
  • 7
    Tushuizen ME, Diamant M, Sturk A, Nieuwland R. Cell-derived microparticles in the pathogenesis of cardiovascular disease: friend or foe. Arterioscler Thromb Vasc Biol 2011;31:4-9.
  • 8
    Shantsila E, Lip GYH. The role of monocytes in thrombotic disorders—insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. Thromb Haemost 2009;102:916-924.
  • 9
    Kato H, Kashiwagi H, Shiraga M, et al. Adiponectin acts as an endogenous antithrombotic factor. Arteriocler Thromb Vasc Biol 2006;26:235-236.
  • 10
    Wolk R, Berger P, Lennon RJ, Brilakis ES, Davison DE, Somers VK. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 2007;28:292-298.
  • 11
    Murakami T, Horigome H, Tanaka K, et al. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb Res 2007;119:45-53.
  • 12
    Goichot B, Grunebaum L, Desprez D, et al. Circulating procoagulant microparticles in obesity. Diabetes Metab 2006;32:82-85.
  • 13
    Regitz-Zacrosek V, Lehmkuhl E, Weickert M. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 2006;95:136-147.
  • 14
    Alberti K, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet 2005;366:1059-1062.
  • 15
    Jy W, Horstman LL, Jimenez JJ, Ahn YS. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004;2:1842-1851.
  • 16
    Bretelle F, Sabatier F, Desprez D, et al. Circulating microparticles: a maker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost 2003;89:486-492.
  • 17
    Amabile N, Guérin AP, Leroyer A, et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005;16:3381-3388.
  • 18
    Robert S, Poncelet P, Lacroix R, et al. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies ? J Thromb Haemost 2008;7:190-197.
  • 19
    Hugel B, Zobairi F, Freyssinet JM. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004;2:1846-1849.
  • 20
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
  • 21
    Esposito K, Ciotola M, Schisano B, et al. Endothelial microparticles correlate with endothelial dysfunction in obese women. J Clin Endocr Metab 2006;91:3676-3679.
  • 22
    Sabatier F, Darmon P, Hugel B, et al. Type 1 and Type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002;51:2840-2845.
  • 23
    Htun P, Fateh-Moghadam S, Tomandl B, et al. Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia. Stroke 2006;37:2283-2287.
  • 24
    Weyrich AS, Elstad MR, Mcever RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996;97:1525-1534.
  • 25
    Grundy SM, Bryan Brewer H, Cleeman JI, Smith SC, Lenfant C, for the Conference Participants. Definition of metabolic syndrome—report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004;109:433-438.
  • 26
    Arteaga RB, Chirinos JA, Soriano AO, et al. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol 2006;98:70-74.
  • 27
    Hanzu FA, Palomo M, Kalko SG, et al. Translational evidence of endothelial damage in obese individuals: inflammatory and prothrombotic responses. J Thromb Haemost 2011;9:1236-1245.
  • 28
    Silkar Z, Oçal G, Berberoglu M, et al. Evaluation of hypercoagulability in obese children with thrombin generation test and microparticle release: effect of metabolic parameters. Clin Appl Thromb Hemost 2011;17:585-589.
  • 29
    Ueba T, Haze T, Sugiyama M, et al. Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome. Thromb Haemost 2008;100:280-285.
  • 30
    Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JWA, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002;106:2442-2447.
  • 31
    Chironi G, Simon A, Hugel B, et al. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arteriocler Thromb Vasc Biol 2006;26:2775-2780.
  • 32
    Mallat Z, Steg PG, Hugel B, et al. Prognostic value of circulating shed membrane pro-coagulant microparticles in patients with severe acute coronary syndrome. A substudy from the register of acute coronary events (GRACE). Circulation 2004;110(Suppl S):575. Abstract
  • 33
    Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol 2011;31:27-33.
  • 34
    Morel O, Luca F, Grunebaum L, et al. Short-term very low-calorie diet in obese females improves the haemostatic balance through the reduction of leptin levels, PAI-1 concentrations and a diminished release of platelet and leukocyte-derived microparticles. Int J Obes 2011;35:1479-1486.
  • 35
    Mithieux G. A synergy between incretin effect and intestinal gluconeogenesis accounting for the rapid metabolic benefits of gastric bypass surgery. Curr Diabetes Rep 2012;12:167-171.
  • 36
    Hanusch-Enserer U, Zorn G, Wojta J, et al. Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J 2009;30:1516-1524.
  • 37
    Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002;105:804-809.
  • 38
    Woelnerhanssen B, Peterli R, Steinert RE, Peters T, Borbély Y, Beglinger C. Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy—a prospective randomized trial. Surg Obes Relat Dis 2011;7:561-568.
  • 39
    Korda M, Kubant R, Patton S, Malinski T. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol 2008;295:H1514-H1521.
  • 40
    Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol 2011;31:27-33.